Walman Optical adds Avulux Migraine and Light Sensitivity lenses to its roster
The lenses have been shown to filter up to 97% of blue, red, and amber light and allows over 70% of soothing green light through.
Image credit: AdobeStock/AndreyPopov
Walman Optical has announced that it has partnered with Avulux Authorized Labs to include Avulux Migraine and Light Sensitivity lenses. The lens is the only clinically proven lens that blocks light wavelengths linked to migraine attacks, according to a news release.
“We are thrilled to offer the Avulux lenses to our customers,” said Glen Funk, vice president of Walman Optical, in the release. “Our commitment is to provide innovative solutions that enrich the lives of patients through better vision. Avulux lenses are a game changer for those affected by light sensitivity and migraine, and we believe this addition will make a significant impact.”
The lenses have been shown to filter up to 97% of blue, red, and amber light and allows over 70% of soothing green light through instead.1 The efficacy of blocking these light forms stems from research in 2010 that found that melanopsin-secreting intrinsically photosensitive retinal ganglion cells could cause migraines and pain.2
As for recent findings of efficacy in Avulux, a 2020 double blind, independently run randomized trial compared the Avulux lens with a true clear sham lens. Migraine pain, the onset of a migraine attack, and both 2 hours and 4 hours after application of either lens was evaluated amongst 79 participants in a 3-week study. Findings demonstrated that if the Avulux lens was applied within the first hour after the onset of a migraine attack, the lens was both statistically and clinically superior to the sham lens.3
Prescription strength lenses were launched in 2022, and was the first lens to be granted an FDA pathway to market using a migraine claim.4 Now, practices that partner with Avulux Authorized Labs receive benefits such as streamlined supply chain, exclusive bulk and wholesale discounts, and special incentives. Eye care providers (ECPs) also receive informational and promotional materials for Avulux lenses for their practices.1
“We value Walman Optical’s partnership because, like us, they are committed to helping independent ECPs build practice growth and deliver an exceptional patient experience,” said Charles Posternack, MD, FACP, FRCPC, president and CEO of Avulux, in the release. “Walman Optical believes in offering the latest in advanced technology combined with superior customer service and continuing education, and we welcome them to our growing roster of labs across the country.”
The Avulux lens is available through eye care providers (ECPs) and optical retailers in the US, Canada, Australia, New Zealand, and the UK.
References:
Avulux Migraine and Light Sensitivity lenses now available through Walman Optical Labs. News release. Walman Optical. September 10, 2024. Accessed September 17, 2024.
Noseda R, Kainz V, Jakubowski M, et al. A neural mechanism for exacerbation of headache by light. Nat Neurosci. 2010;13(2):239-245. doi:10.1038/nn.2475
Posternack C, Kupchak P, Capriolo AI, Katz BJ. Targeting the intrinsically photosensitive retinal ganglion cell to reduce headache pain and light sensitivity in migraine: a randomized double-blind trial. 2023;113:22-31. doi:10.1016/j.jocn.2023.04.015
Born From Cutting Edge Research. Avulux. Accessed September 17, 2024. https://ecp.avulux.com/about-avulux/
